CDK7调控多发性骨髓瘤中E2F和MYC驱动的增殖与代谢脆弱性
研究显示CDK7表达与多发性骨髓瘤患者细胞的E2F和MYC转录程序正相关,选择性靶向CDK7可扰动细胞周期蛋白依赖性激酶/Rb轴削弱E2F活性,并损害MYC调控的代谢基因签名导致糖酵解缺陷和乳酸生成减少。共价小分子抑制剂YKL-5-124对正常细胞影响极小,在多种小鼠模型中引起肿瘤消退并提高生存率,包括MYC依赖性MM的基因工程小鼠模型。
要点
- CDK7表达与MM患者细胞的E2F和MYC转录程序正相关。
- YKL-5-124抑制CDK7可削弱E2F活性并损害MYC调控的代谢基因签名。
- YKL-5-124在多种小鼠MM模型中引起肿瘤消退并提高生存率。
核心结论
- CDK7是支持MM生长和存活的致癌细胞程序的主调控因子,也是 valuable 治疗靶点,为YKL-5-124的临床开发提供依据。
研究设计与样本
- 临床前研究:分析MM患者细胞的CDK7表达与E2F/MYC转录程序相关性,使用共价小分子抑制剂YKL-5-124进行体外和体内实验,包括多种小鼠MM模型及MYC依赖性MM基因工程小鼠模型。
主要发现
- CDK7表达与MM患者细胞的E2F和MYC转录程序正相关。
- 选择性靶向CDK7通过扰动细胞周期蛋白依赖性激酶/Rb轴削弱E2F活性。
- CDK7抑制损害MYC调控的代谢基因签名,导致MM细胞糖酵解缺陷和乳酸生成水平降低。
- YKL-5-124抑制CDK7对正常细胞影响极小,在多种小鼠MM模型中引起肿瘤消退并提高生存率。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic targeting of CDK7 has proven beneficial in preclinical studies, yet the off-target effects of currently available CDK7 inhibitors make it difficult to pinpoint the exact mechanisms behind MM cell death mediated by CDK7 inhibition. Here, we show that CDK7 expression positively correlates with E2F and MYC transcriptional programs in cells from patients with multiple myeloma (MM); its selective targeting counteracts E2F activity via perturbation of the cyclin-dependent kinases/Rb axis and impairs MYC-regulated metabolic gene signatures translating into defects in glycolysis and reduced levels of lactate production in MM cells. CDK7 inhibition using the covalent small-molecule inhibitor YKL-5-124 elicits a strong therapeutic response with minimal effects on normal cells, and causes in vivo tumor regression, increasing survival in several mouse models of MM including a genetically engineered mouse model of MYC-dependent MM. Through its role as a critical cofactor and regulator of MYC and E2F activity, CDK7 is therefore a master regulator of oncogenic cellular programs supporting MM growth and survival, and a valuable therapeutic target providing rationale for development of YKL-5-124 for clinical use.
引用
- Yao Y, Ng JF, Park WD, et al. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. 2023. PMID: 36877894. doi:10.1182/blood.2022018885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。